Clinical Trial Update: SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

View source ↗

Summary

Post-marketing surveillance update for SAPHNELO (anifrolumab) in systemic lupus erythematosus in Japan; the PMS is active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Sponsor: AstraZeneca | Conditions: Lupus Erythematosus, Systemic | Status: ACTIVE_NOT_RECRUITING